Pura Vida Investments LLC Increases Position in LivaNova PLC (LIVN)

Pura Vida Investments LLC lifted its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 10.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 154,273 shares of the company’s stock after buying an additional 14,271 shares during the quarter. LivaNova comprises 4.9% of Pura Vida Investments LLC’s investment portfolio, making the stock its 2nd biggest position. Pura Vida Investments LLC owned about 0.32% of LivaNova worth $10,808,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of LIVN. Russell Investments Group Ltd. purchased a new stake in LivaNova in the 2nd quarter worth approximately $957,000. Strs Ohio purchased a new stake in LivaNova in the 2nd quarter worth approximately $673,000. Bessemer Group Inc. purchased a new stake in LivaNova in the 2nd quarter worth approximately $220,000. Schwab Charles Investment Management Inc. lifted its stake in LivaNova by 91.8% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 236,427 shares of the company’s stock worth $14,472,000 after purchasing an additional 113,176 shares in the last quarter. Finally, Arizona State Retirement System lifted its stake in LivaNova by 1.7% in the 2nd quarter. Arizona State Retirement System now owns 18,300 shares of the company’s stock worth $1,120,000 after purchasing an additional 300 shares in the last quarter. Institutional investors and hedge funds own 86.07% of the company’s stock.

LivaNova PLC (NASDAQ:LIVN) opened at $81.56 on Thursday. The company has a market cap of $3,938.88, a price-to-earnings ratio of 23.55, a PEG ratio of 2.45 and a beta of 0.61. LivaNova PLC has a twelve month low of $44.58 and a twelve month high of $88.56. The company has a quick ratio of 1.42, a current ratio of 2.03 and a debt-to-equity ratio of 0.04.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Thursday, November 2nd. The company reported $0.93 EPS for the quarter, topping the Zacks’ consensus estimate of $0.76 by $0.17. The firm had revenue of $309.70 million for the quarter, compared to analyst estimates of $301.22 million. LivaNova had a net margin of 4.63% and a return on equity of 9.33%. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.78 EPS. equities research analysts expect that LivaNova PLC will post 3.33 earnings per share for the current fiscal year.

In related news, Director Hugh M. Morrison sold 1,830 shares of the stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $88.00, for a total transaction of $161,040.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction on Friday, September 15th. The shares were sold at an average price of $68.55, for a total transaction of $68,550.00. Following the transaction, the director now directly owns 57,296 shares in the company, valued at approximately $3,927,640.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 6,830 shares of company stock worth $557,100. 0.28% of the stock is owned by insiders.

Several analysts have issued reports on LIVN shares. Needham & Company LLC started coverage on shares of LivaNova in a research note on Wednesday, August 23rd. They issued a “hold” rating on the stock. Jefferies Group started coverage on shares of LivaNova in a research note on Friday, September 8th. They issued a “buy” rating and a $76.00 target price on the stock. Piper Jaffray Companies reiterated an “overweight” rating and issued a $75.00 target price on shares of LivaNova in a research note on Tuesday, September 12th. Canaccord Genuity reissued a “hold” rating and issued a $71.00 price target on shares of LivaNova in a report on Wednesday, September 20th. Finally, ValuEngine raised shares of LivaNova from a “hold” rating to a “buy” rating in a report on Thursday, November 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $79.71.

ILLEGAL ACTIVITY NOTICE: This story was first reported by Week Herald and is the sole property of of Week Herald. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://weekherald.com/2017/12/14/pura-vida-investments-llc-increases-position-in-livanova-plc-livn.html.

LivaNova Profile

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.

Institutional Ownership by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply